Ginkgo Bioworks Holdings Inc Stock Price, News & Analysis

Ginkgo Bioworks (NYSE: DNA) and Agricen announced on Dec 17, 2025 the completion of an initial collaboration to develop and optimize a low-cost, efficient fermentation process for complex bacterial strains used in an Agricen soil amendment product.

The work reduced fermentation time for challenging microbes, freed Agricen to focus on pipeline development, and demonstrated Ginkgo's platform capabilities from small screening through commercial volumes of 20 L to 3,000 L.

Ginkgo Bioworks (NYSE: DNA) announced a partnership with Deep Origin on a 4.5-year, ARPA-H funded CATALYST project called PREDICTS to develop a computational platform for drug safety.

Ginkgo will use its Datapoints platform to generate high-throughput, structured datasets for AI model training using small-molecule and genetic perturbations across multiple cell and tissue types. Planned readouts include cell type-specific toxicity endpoints, DRUG-seq transcriptomics, and cell painting.

The collaboration aims to support safer therapeutics through multi-omics data generation and in vitro models integrated with AI over the project term.

Ginkgo Bioworks (NYSE: DNA) was awarded a four-year, up to $47M contract by Pacific Northwest National Laboratory's EMSL to co-design, build, and integrate a High‑Throughput Automated Phenotyping Platform (HTP‑APP) for the DOE Microbial Molecular Phenotyping Capability (M2PC).

The modular HTP‑APP will use Ginkgo Automation's Catalyst scheduling software and Reconfigurable Automation Carts (RACs) to automate end‑to‑end workflows, support BSL‑2 operations, enable remote cloud‑lab planning, and generate multimodal data intended for AI/ML analysis.

STRM.BIO (DNA) was awarded an ARPA-H EMBODY contract on Dec 3, 2025 with up to $8.4 million to support a first-phase program advancing its proprietary megakaryocyte-derived extracellular vesicle (MV) delivery platform for in vivo cell and gene therapy.

STRM.BIO will act as prime, partnering with Ginkgo (DNA), the University of British Columbia, and Advanced Bioprocess Services to develop bone marrow-targeted in vivo CAR-T therapeutics using MV delivery and self-amplifying RNA expertise.

Ginkgo Bioworks (NYSE: DNA) reported third quarter 2025 results on November 6, 2025: Total revenue $39M (down 56% year‑over‑year, prior year included $45M non‑cash deferred revenue), Cell Engineering $29M, Biosecurity $9M. GAAP net loss was $81M and Adjusted EBITDA was $(56)M. Cash, cash equivalents and marketable securities were $462M as of September 30, 2025.

Company reaffirmed full‑year 2025 guidance: Total revenue $167–$187M, Cell Engineering $117–$137M, Biosecurity at least $40M. Business highlights include a multi‑year extension with Bayer and a BARDA project award up to $22.2M. A webcast and replay are available for investors.

Ginkgo Bioworks (NYSE: DNA) was awarded a BARDA BioMaP-Consortium project agreement on November 3, 2025 to develop cost-reducing, scalable domestic biomanufacturing innovations for monoclonal antibodies (mAbs) against filoviruses such as Ebola (EBOV) and Sudan virus (SUDV).

The contract value is up to $22.2 million. Ginkgo will lead a partner team (Advanced BioScience Laboratories, Isolere Bio by Donaldson, NeuImmune, and ProteoNic) to integrate technologies across the mAb production process and to produce an anti-filovirus mAb cocktail (1C3 and 1C11) discovered at Emory University. The project is funded in whole or in part by BARDA/ASPR under OT number 75A50123D00003.

Ginkgo Bioworks (NYSE: DNA) announced an extension of its multi-year strategic partnership with Bayer on Oct 31, 2025 to continue joint R&D on agricultural biologicals, including microbial nitrogen fixation. The collaboration, which began in 2017, keeps Bayer's right to commercialize resulting biological products as complements to synthetic fertilizers.

Ginkgo will continue independent partnerships and advance its agricultural biologicals platform, which includes an R&D site in West Sacramento.

Ginkgo Bioworks (NYSE: DNA) will host a third-quarter 2025 results presentation and live Q&A on Thursday, November 6, 2025 beginning at 4:30 p.m. ET. The presentation will review business performance for the quarter ended September 30, 2025.

Webcast details and the replay will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com. Investors can submit questions in advance via X using hashtag #GinkgoResults or by emailing investors@ginkgobioworks.com.

Ginkgo Bioworks (NYSE: DNA) announced a collaboration with STRM.BIO and the University of British Columbia under ARPA-H's EMBODY program to develop in vivo CAR therapies for autoimmune diseases on Oct 23, 2025.

The project, INVITE-ME, will combine STRM.BIO's megakaryocyte-derived extracellular vesicle delivery platform with Ginkgo's RNA construct design, nucleic acid AI, and immune cell engineering to pursue long-lived, tissue-specific CAR expression that could selectively eliminate autoreactive B and T cells without ex vivo manipulation.